Cargando…

Erectile dysfunction as a marker of endocrine and glycemic disorders

PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzilli, R., Zamponi, V., Olana, S., Mikovic, N., Cimadomo, D., Defeudis, G., Faggiano, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270283/
https://www.ncbi.nlm.nih.gov/pubmed/35366160
http://dx.doi.org/10.1007/s40618-022-01788-5
_version_ 1784744428325306368
author Mazzilli, R.
Zamponi, V.
Olana, S.
Mikovic, N.
Cimadomo, D.
Defeudis, G.
Faggiano, A.
author_facet Mazzilli, R.
Zamponi, V.
Olana, S.
Mikovic, N.
Cimadomo, D.
Defeudis, G.
Faggiano, A.
author_sort Mazzilli, R.
collection PubMed
description PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 2013 to 2020 were included. The ED diagnosis was made using the International-Erectile-Function-Index-5 questionnaire. ED severity was considered according to presence/absence of spontaneous erections, maintenance/achievement deficiency. All patients were subjected to search for sociodemographic and clinical characteristics: age, ethnicity, marital status, previous use of PDE5i, previous prostatectomy, diabetes mellitus (DM), prediabetes, endocrine dysfunctions. RESULTS: The mean ± SD age was 54.3 ± 13.7 years. The 19.1% (255/1332) of patients were already in treatment for prediabetes/diabetes or endocrine dysfunctions. Among the remaining 1077, the prevalence of previously unknown endocrine and glycemic disorders was 30% (323/1077). Among them, 190/323 subjects (58.8%) were affected by hypogonadism, with high estradiol level observed in 8/190 (4.2%). The prevalence of new glycemic alterations was 17.3% (56/323) [specifically, 32/56 (57.1%) DM, and 24/56 (42.9%) prediabetes]. A thyroid dysfunction was observed in 40/323 subjects (12.3%) and hyperprolactinemia in 37/323 (11.5%). Patients with new diagnosis of DM showed more severe form of ED compared to the total group {difficulty in the achievement of erection: 46/56 [82.2%, vs 265/1332 (19.9%), p < 0.05]; absence of spontaneous erection 23/56 [41.1%, vs 321/1332 (24.1%), p < 0.05]}. CONCLUSION: ED is an early marker of endocrine/glycemic disorder, and a previously unknown dysfunction was found in more than a quarter of patients. A newly diagnosed DM is associated with ED severity, especially in elderly man and in presence of hypertension.
format Online
Article
Text
id pubmed-9270283
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92702832022-07-10 Erectile dysfunction as a marker of endocrine and glycemic disorders Mazzilli, R. Zamponi, V. Olana, S. Mikovic, N. Cimadomo, D. Defeudis, G. Faggiano, A. J Endocrinol Invest Original Article PURPOSE: The aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders. METHODS: 1332 patients referred for ED from 2013 to 2020 were included. The ED diagnosis was made using the International-Erectile-Function-Index-5 questionnaire. ED severity was considered according to presence/absence of spontaneous erections, maintenance/achievement deficiency. All patients were subjected to search for sociodemographic and clinical characteristics: age, ethnicity, marital status, previous use of PDE5i, previous prostatectomy, diabetes mellitus (DM), prediabetes, endocrine dysfunctions. RESULTS: The mean ± SD age was 54.3 ± 13.7 years. The 19.1% (255/1332) of patients were already in treatment for prediabetes/diabetes or endocrine dysfunctions. Among the remaining 1077, the prevalence of previously unknown endocrine and glycemic disorders was 30% (323/1077). Among them, 190/323 subjects (58.8%) were affected by hypogonadism, with high estradiol level observed in 8/190 (4.2%). The prevalence of new glycemic alterations was 17.3% (56/323) [specifically, 32/56 (57.1%) DM, and 24/56 (42.9%) prediabetes]. A thyroid dysfunction was observed in 40/323 subjects (12.3%) and hyperprolactinemia in 37/323 (11.5%). Patients with new diagnosis of DM showed more severe form of ED compared to the total group {difficulty in the achievement of erection: 46/56 [82.2%, vs 265/1332 (19.9%), p < 0.05]; absence of spontaneous erection 23/56 [41.1%, vs 321/1332 (24.1%), p < 0.05]}. CONCLUSION: ED is an early marker of endocrine/glycemic disorder, and a previously unknown dysfunction was found in more than a quarter of patients. A newly diagnosed DM is associated with ED severity, especially in elderly man and in presence of hypertension. Springer International Publishing 2022-04-02 2022 /pmc/articles/PMC9270283/ /pubmed/35366160 http://dx.doi.org/10.1007/s40618-022-01788-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Mazzilli, R.
Zamponi, V.
Olana, S.
Mikovic, N.
Cimadomo, D.
Defeudis, G.
Faggiano, A.
Erectile dysfunction as a marker of endocrine and glycemic disorders
title Erectile dysfunction as a marker of endocrine and glycemic disorders
title_full Erectile dysfunction as a marker of endocrine and glycemic disorders
title_fullStr Erectile dysfunction as a marker of endocrine and glycemic disorders
title_full_unstemmed Erectile dysfunction as a marker of endocrine and glycemic disorders
title_short Erectile dysfunction as a marker of endocrine and glycemic disorders
title_sort erectile dysfunction as a marker of endocrine and glycemic disorders
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270283/
https://www.ncbi.nlm.nih.gov/pubmed/35366160
http://dx.doi.org/10.1007/s40618-022-01788-5
work_keys_str_mv AT mazzillir erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT zamponiv erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT olanas erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT mikovicn erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT cimadomod erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT defeudisg erectiledysfunctionasamarkerofendocrineandglycemicdisorders
AT faggianoa erectiledysfunctionasamarkerofendocrineandglycemicdisorders